ipamorelin vs cjc-1295
updated
ipamorelin (tier C) vs cjc-1295 (tier A): what each is, half-life and source counts side by side.
the difference
checked
the combination makes pharmacological sense because GHRH-receptor and ghrelin-receptor signaling can amplify GH release through different routes. that does not make the common anti-aging outcomes proven, and the with-DAC vs no-DAC CJC question changes the physiology.
- reptides claim check: cjc-1295 + ipamorelin stack
- Teichman SL et al. J Clin Endocrinol Metab 2006 (PMID 16352683)
- Ionescu M et al. J Clin Endocrinol Metab 2006 (PMID 17018654)
- Raun K et al. Eur J Endocrinol 1998 (PMID 9849822)
- Gobburu JV et al. Pharm Res 1999 (PMID 10496658)
a PubMed search and a ClinicalTrials.gov search on October 24, 2026 found no human trial that gave cjc-1295 and ipamorelin together.
- PubMed search: ipamorelin with CJC-1295 or modified GRF 1-29 (October 24, 2026)
- ClinicalTrials.gov search: ipamorelin (October 24, 2026)
- ClinicalTrials.gov search: CJC-1295 (October 24, 2026)
the human cjc-1295 studies tested the form with DAC, which binds to albumin and kept GH and IGF-1 raised for days in healthy adults; products sold as cjc-1295 without DAC lack that albumin-binding group, so those results do not carry over to them.
- Teichman SL et al. J Clin Endocrinol Metab 2006 (PMID 16352683)
- Jetté L et al. Endocrinology 2005 (PMID 15817669)
a Drugs@FDA search on October 24, 2026 found no FDA approval for either.
- Drugs@FDA search via openFDA: ipamorelin, no matches (October 24, 2026)
- Drugs@FDA search via openFDA: CJC-1295, no matches (October 24, 2026)
ipamorelin · tier C
Ipamorelin is a synthetic pentapeptide ghrelin-receptor agonist. People seek it for sleep, recovery, and body composition, but direct human studies measured an acute intravenous GH pulse and a negative ileus outcome.
tier rationale
C reflects dose-related human growth-hormone release plus a 114-person clinical efficacy trial that missed its primary endpoint. No controlled study measured the marketed fitness, recovery, or sleep outcomes.
cjc-1295 · tier A
growth hormone without injecting growth hormone. tells your pituitary to make its own. paired with ipamorelin.
tier rationale
a synthetic GHRH analog engineered by ConjuChem to have a dramatically extended half-life, achieved by covalent binding to endogenous albumin via a drug affinity complex (DAC). comes in two forms: with DAC (6-8 day half-life, single weekly dose) and without DAC (short-acting, "Mod GRF 1-29," used in stacked protocols). the GHRH-receptor agonism mechanism is well-characterized, but a phase 2 HIV-lipodystrophy trial was discontinued after a patient death (attending physician concluded unrelated). A-tier based on mechanism plausibility and consistent user reports from peptide clinics, held back from S by the absence of a completed clinical program and no FDA approval.
at a glance
| ipamorelin | cjc-1295 | |
|---|---|---|
| tier | C | A |
| category | gh / growth | gh / growth |
| sources | 11 | 20 |
| claims evaluated | n/a | 6 |
| half-life | about 2 hours after intravenous infusion | ~6-8 days |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.